Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

NCT03913559 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT03913559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 2
Overall status
Terminated
Start date
May 14, 2019
Completion date
September 15, 2025
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia